Biotechnology and IPR in China: An FAS persepctive

354 views

Published on

Published in: Business, Technology
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
354
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide
  • Hi. I’m Michael Henney of the Foreign Agricultural Service – FAS.
    I’m happy to be able to talk to you today about the role that FAS plays in the marketing of biotech products in China.
  • Structurally speaking, there are a number of offices and people in FAS and USDA who work together on ag. biotech issues with China.
  • Biotechnology and IPR in China: An FAS persepctive

    1. 1. Agricultural Biotechnology and Intellectual Property Rights in China: An FAS and USDA Perspective Michael Henney U.S. Department of Agriculture Foreign Agricultural Service June 26, 2007 Michael.Henney@fas.usda.gov
    2. 2. FAS and USDA on Biotech and China • FAS, Office of Scientific and Technical Affairs, New Technologies and Production Methods Branch • FAS, Office of Country and Regional Affairs, China Desk • FAS Beijing • USDA’s Animal and Plant Health Inspection Service, Biotechnology Regulatory Service • USDA’s Plant Variety Protection Office • USDA’s Agricultural Research Service, Office of Technology Transfer
    3. 3. An Overview of Biotech Products in China • largest market (> 30%) for U.S.- produced soybeans, greater than $2.5 billion FY2006 • emerging market for U.S-produced corn • domestic production of cotton • potential domestic production of rice, etc.
    4. 4. Challenges for Biotech Products in China: I. Regulatory • Biosafety regulatory system – lack of synchrony between U.S. and Chinese biosafety approvals • infrequent meetings of National Biosafety Committee • extensive in-country biosafety testing required • requirement for approval in country of origin prior to application submission – no clearly established policy on stacked event biotech products – growing interest to develop capacities for detection testing
    5. 5. Challenges for Biotech Products in China: II. Business Practices • Constraints on Foreign Direct Investment for biotech industries • Trademarks (first to file system in China)
    6. 6. Challenges for Biotech products in China: III. IPR • Currently no ability to patent biotech products, only processes • requirement for disclosure of source of genetic material in patent application • 1978 UPOV convention for Plant Variety Protection • Lack of IPR enforcement?
    7. 7. The Interface of Regulatory and IPR issues: I • Blurred lines between responsibilities – government officials vs. academy, university and institute faculty – basic researchers, product developers, biosafety researchers, risk assessors, National Biosafety Committee members sometimes all the same people
    8. 8. The Interface of Regulatory and IPR Issues: II • Concern about management of information and materials required for application submission – seed for biosafety testing, PVP testing and reference material for detection testing – protocols for detection testing – data on product development, molecular information
    9. 9. FAS Action on Regulatory and IPR Issues: I. Structure • FAS work with U.S. Patent and Trademark Office on overarching IPR issues • U.S. Embassy Beijing IPR Task Force (coordination on all IPR issues) • FAS Beijing IPR office (run through Ag. Trade Office) • Regular Coordination with Stakeholders (e.g.- Crop Life China Industry Group)
    10. 10. FAS and USDA Action on Regulatory and IPR Issues: II. Fora • High-Level Biotechnology Working Group (BWG) and Technical Working Group (TWG) on biotech regulatory and trade policy issues (with Chinese Ministry of Agriculture, others) • Joint Committee on Cooperation in Agriculture (JCCA) • U.S.–China Joint Commission on Commerce and Trade (JCCT), IPR Working Group

    ×